अApnaFunda
Menu

Rubicon Research vs Bliss GVS Pharma

Both in Pharmaceuticals: Generic · as of 9 Nov · Methodology

RUBICONBLISSGVSChange the comparison →
At a glanceNov 2026
RUBICONBLISSGVSROCE28.0%17.0%Operating margin24.0%27.0%P/E100.2x50.9xDebt / Equity0.2x0.0x
Highlight: the higher value, or the lower for P/E and debt.Full snapshot →

Where the return came from

Price change over 3 years, split into profit, share count and P/E.

BLISSGVS Net profit growth: +145 pts+145 ptsShare count change: +6 ptsP/E change: +214 pts+214 pts +365% BLISSGVS Net profit growth: +145 pts+145 ptsShare count change: +6 ptsP/E change: +214 pts+214 pts +365%
Net profit growthShare count changeP/E changeUnexplained
PointsPriceProfitSharesP/E
BLISSGVS+365%+145+6+214

Not shown for RUBICON: earnings were negative at one end of the window or there is not enough history.

Rank within sector

Percentile among sector peers, by month. Rows marked ↓ rank lower values higher.

Rubicon ResearchHealth Technology
ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21202320242025Nov '26
Lower rank Higher rank Not enough data
Bliss GVS PharmaHealth Technology
ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21202320242025Nov '26
Lower rank Higher rank Not enough data

Snapshot

Share price: close of 9 Nov; other figures: latest month, Nov 2026.

MetricRUBICONBLISSGVS
Size and price
Share Price₹1771.70₹654.75
Market Cap₹29338 cr₹6958 cr
Revenue (TTM)₹1936 cr₹1005 cr
Net Profit (TTM)₹289 cr₹142 cr
Valuation
P/E100.2x50.9x
P/B22.8x5.8x
P/S15.2x6.9x
Profitability
ROCE28.0%17.0%
ROE22.7%11.5%
Operating margin24.0%27.0%
MetricRUBICONBLISSGVS
Balance sheet and cash
Debt / Equity0.2x0.0x
Interest cover10.3x29.7x
Cash conversion (3Y)0.8x1.1x
Cash Conversion Cycle371d244d
Ownership
Promoter holding59.8%35.0%
FII Holding7.5%8.1%
DII Holding9.4%9.5%
Share Count Change (1Y)13.3%0.0%
Price behaviour
12M momentum170.1%294.5%
Drawdown from Peak-2.6%-5.7%
Volatility (1Y)43.7%61.0%
Open all in the observatory →Health Technology sector →

Comparison is descriptive and historical. Highlights mark the higher or lower value on a metric, not a better investment.

Methodology

How comparisons are computed

Definitions and known limitations.

Data and timing

Every figure is a monthly, point-in-time value: fundamentals join a month only 60 days after the quarter ends, so a month never shows a result that would not yet have been published. The numbers are the same ones each company's own page shows.

Share price

Monthly closes, rebased to 100 at the first month every company in the comparison has a price. A company listed later moves the start of the chart for all of them.

Metrics over time

Months with a missing value are left as gaps. On a log scale, equal vertical distances are equal ratios, and months with a non-positive value are gaps too. Revenue is indexed to 100 at the first month every company has a positive figure.

Where the return came from

Price = P/E × net profit ÷ share count, so a price return splits into percentage points from net profit growth, share count change and the change in P/E. It is not shown for a company whose earnings were negative at one end of the window.

Rank within sector

Each cell is the company's percentile rank among its own sector's companies that month. Rows marked ↓ are inverted: lower debt, a shorter cash cycle and a lower P/E rank higher. Ranks use today's listed companies in the sector and need at least 5 peers with a value. Banks and financial companies are ranked on a different set of metrics, so their blocks show different rows.

Highlights

A highlight marks the higher value, or the lower value for P/E, P/B, P/S, debt, working-capital days, share count change and volatility. It marks a number, not a better investment. P/E, P/B and P/S only count when positive.

Feedback